文献速递主动脉疾病

血浆胱抑素B与腹主动脉瘤及后期手术修复需求的关联:VIVA试验的子研究

Plasma Cystatin B Association With Abdominal Aortic Aneurysms and Need for Later Surgical Repair: A Sub-study of the VIVA Trial.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-09-24

该研究基于Viborg血管筛查(VIVA)试验,比较腹主动脉瘤(AAA)患者与年龄匹配对照的血浆胱抑素B水平,发现AAA患者显著更高,且基线胱抑素B三分位与AAA存在及后期手术修复相关。

要点

  • AAA患者血浆胱抑素B水平显著高于年龄匹配对照(p < 0.001)。
  • 基线胱抑素B三分位与AAA存在相关:未调整OR 1.656(p < 0.001),调整后OR 1.526(p < 0.001)。
  • 基线胱抑素B三分位与后期AAA手术修复相关:未调整HR 1.387(p < 0.001),调整后HR 1.523(p < 0.001)。

核心结论

  • 与既往显示胱抑素C负向关联AAA发展的研究相反,本研究报告胱抑素B与AAA大小正相关,且基线胱抑素B三分位与AAA存在及后期手术修复需求相关。
  • 作者认为这两种胱抑素可能以不同机制抑制组织蛋白酶活性并参与AAA。

研究设计与样本

  • VIVA筛查试验的子研究,从Viborg血管(VIVA)AAA筛查试验中选取AAA患者及年龄匹配对照的血浆样本。
  • 采用酶联免疫吸附试验测定血浆胱抑素B,使用t检验、logistic回归、Pearson相关和Cox回归分析胱抑素B与AAA大小、增长率及作为AAA标志物的关系。

主要发现

  • AAA患者血浆胱抑素B水平显著高于对照(p < 0.001)。
  • Logistic回归显示基线胱抑素B三分位与AAA存在相关:未调整OR 1.656(p < 0.001),调整外周动脉疾病(PAD)、慢性阻塞性肺疾病(COPD)及既往缺血事件后OR 1.526(p < 0.001)。
  • t检验显示胱抑素B与筛查时PAD、COPD医院诊断、既往动脉粥样硬化事件及低剂量阿司匹林使用显著相关。
  • Pearson相关显示胱抑素B与AAA大小正相关且显著(r = 0.15;p < 0.001)。
  • Cox回归显示基线胱抑素B三分位与后期AAA手术修复相关:未调整HR 1.387(p < 0.001),调整PAD、COPD、既往缺血事件及最大肾下腹主动脉直径后HR 1.523(p < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: The development of an abdominal aortic aneurysm (AAA) involves extensive extracellular matrix remodelling, leading to aortic wall weakening. This process is mediated by proteases, including cysteinyl cathepsins. Cystatins are their endogenous inhibitors. This study tested whether plasma cystatin B levels in patients with AAA differed from those of healthy controls. METHODS: Plasma samples from patients with AAA and age matched controls were selected from the Viborg Vascular (VIVA) screening trial for AAA. Enzyme linked immunosorbent assay determined plasma cystatin B. T-test, logistic regression, Pearson's correlation and Cox regression tested whether plasma cystatin B correlates with AAA size and growth rate, or serves as a marker for AAA. RESULTS: Plasma cystatin B levels were significantly higher in patients with AAA than in controls (p < 0.001). Logistic regression analysis showed that cystatin B tertile at baseline was associated with the presence of AAA before (odds ratio [OR] 1.656; p < 0.001) and after adjustment for peripheral arterial disease (PAD), chronic obstructive pulmonary disease (COPD), and previous ischaemic events (OR 1.526; p < 0.001). A t-test showed a significant association between cystatin B and PAD at screening, hospital diagnosis of COPD, previous atherosclerotic events, and use of low dose aspirin. Pearson's correlation test showed positive and significant associations between cystatin B and AAA size (r = 0.15; p < 0.001). Cox regression test showed that plasma cystatin B tertile at baseline was associated with later AAA surgical repair before (hazard ratio [HR] 1.387; p < 0.001) and after adjustment for PAD, COPD, previous ischaemic event, and maximum infrarenal aortic diameter (HR 1.523; p < 0.001). CONCLUSION: In contrast to prior studies that showed that cystatin C is negatively associated with AAA development, this study demonstrated a positive association between cystatin B and AAA size and associations between cystatin B tertile at baseline and AAA presence and need for later surgical repair. It is possible that these two cystatins inhibit cathepsin activity and participate in AAA with different mechanisms.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang Y, Liu CL, Lindholt JS, et al. Plasma Cystatin B Association With Abdominal Aortic Aneurysms and Need for Later Surgical Repair: A Sub-study of the VIVA Trial. Eur J Vasc Endovasc Surg. 2018. PMID: 30262158. doi:10.1016/j.ejvs.2018.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。